Valeant Pharmaceuticals International Inc (VRX.TO) is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters.
drugmaker
Breaking News
Establishing a tax domicile abroad to avoid U.S. taxes is a hot strategy in corporate America, but many companies that have done such "inversion" deals have failed to produce above-average returns for investors, a Reuters analysis has found.
Vivus wanted to reach a settlement with the biggest investors for board control.
Adcock Ingram Holdings Ltd. received a non-binding proposal from Chilean drug manufacturer CFR Pharmaceuticals SA for US$1.3 billion.
Cipla Ltd offers to take over Cipla Medpro South Africa.
Subscribe to VCpost newsletter
Most Popular
- Former CEO Shoots Himself to Commit Suicide After Receiving $25 Million Record-Breaking Fine for Fraud at Steinhoff
- Xi Jinping Warns Dutch PM That 'No Force' Can Stop China's Technological Advancement Amid Export Restrictions
- Disney Investor Nelson Peltz Criticizes the Company’s 'Woke' Strategy, Questioning 'Black Panther' and 'The Marvels' Films
- Major AI Companies Unite to Create the World's First Artificial Superintelligence Alliance Worth $7.6 Billion
- Social Security Benefits to Increase for Some Seniors After Addressing Overpayment Issues
- Businessman Brutally Murdered Allegedly by 4 of His Workers Who Swung an Axe Into His Head
- North Korea Refuses Peace Talk With Japan Unless They Confront Their 'Brutal' History; Business Relations at Risk
- Hunter Biden Asks Court to Junk $1.4 Million Tax Evasion Case as Politically Motivated, But Judge Appears Skeptical